Regulatory update: the tax regime for foreign-owned entities in Kazakhstan in the pharmaceuticals sector

Foreign pharmaceutical companies operating in Kazakhstan — whether through a local subsidiary, a representative office, or a distribution entity — face a materially different tax environment from that which governed the sector three years ago. Across corporate income tax treatment, VAT relief on pharmaceutical products, and transfer-pricing obligations affecting cross-border supply chains, the Kazakh legislature has introduced changes that reshape the compliance baseline for every foreign-owned entity with a pharmaceutical nexus. For regional GCs managing multi-jurisdictional EAEU portfolios, and for inbound investors assessing Kazakhstan market entry in the pharmaceuticals sector, understanding the current framework is no longer optional groundwork — it is the starting point for any structuring decision.

Kazakhstan's Tax Code has always contained differentiated treatment for the pharmaceutical sector, primarily through reduced VAT rates on qualifying medicines and a licensing layer that creates regulatory preconditions for tax-preferential treatment. The significant shift in recent years has been directional: the legislature has progressively narrowed the scope of VAT exemptions available on domestic pharmaceutical sales while simultaneously tightening the conditions under which foreign-owned entities may claim those exemptions.

Under the prior framework, a wide range of pharmaceutical products — both imported and locally manufactured — attracted either a zero rate or a reduced rate of VAT on domestic turnover, with relatively permissive conditions for the exporting foreign parent to recover input tax through its Kazakh subsidiary. The current position is more nuanced. VAT relief on pharmaceutical products remains available but is now linked directly to product registration status with the authorised regulatory body and, critically, to the entity's compliance standing — meaning that a foreign-owned entity with outstanding transfer-pricing or controlled-transaction documentation deficiencies may find its VAT relief position contested during audit.

The corporate income tax rate applicable to foreign-owned entities in Kazakhstan has not changed at the headline level. What has changed is the enforcement posture of the Kazakh tax authority toward foreign-owned pharmaceutical entities. Transfer-pricing documentation requirements — always present in the Kazakh Tax Code for controlled transactions — are now applied with materially greater rigour to pharmaceutical supply chains. The principal trigger is the cross-border pricing of active pharmaceutical ingredients (APIs) and branded products imported from a related foreign supplier. Kazakh tax inspectors have become considerably more active in challenging the arm's length character of these prices, with reference to both OECD guidelines (which Kazakhstan has adopted by reference) and sector-specific comparables.

For entities structured as representative offices rather than incorporated subsidiaries, the position remains more constrained. Representative offices in Kazakhstan may not conduct commercial activity and are therefore excluded from the VAT registration regime entirely; their tax exposure is limited to deemed permanent establishment risk if their actual activities exceed the scope of preparatory and auxiliary functions. In the pharmaceutical sector, where a representative office typically supports registration, pharmacovigilance, and medical affairs activities, the boundary between permitted auxiliary activity and taxable commercial presence is frequently tested during audit.

"The shift in enforcement posture around transfer pricing in Kazakhstan's pharmaceutical sector has been the most consequential practical development of the past two years — foreign parent companies need to treat their Kazakhstan supply chain pricing as audit-ready from day one, not as a retrospective documentation exercise." — Aigerim Serikbayeva, Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs and Market Entry

[CTA: For foreign pharmaceutical companies assessing their current Kazakhstan tax position, or structuring a new market entry, we can coordinate analysis through our regional counsel network — info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

The changes described above do not affect all foreign pharmaceutical presences in Kazakhstan equally. The practical impact depends on entity type, supply chain structure, and the nature of the products concerned.

Foreign pharmaceutical companies operating through a fully incorporated Kazakh subsidiary — a joint-stock company or a limited liability partnership — bear the fullest compliance burden. They are subject to corporate income tax on Kazakh-source profits, VAT registration obligations once turnover thresholds are crossed, and transfer-pricing documentation requirements on all controlled transactions. Where the subsidiary imports finished pharmaceutical products or APIs from a related foreign entity, every such transaction is in principle a controlled transaction requiring arm's length documentation. The documentation standard expected by Kazakh inspectors now aligns closely with the OECD three-tier approach (master file, local file, country-by-country report for groups above the relevant threshold), though the precise local implementation has its own procedural requirements.

Companies operating through distribution arrangements with an independent Kazakh distributor face a different — and often underestimated — risk. Where the foreign company exercises significant control over pricing, promotional activity, or product registration in Kazakhstan, the independent distributor structure may be recharacterised as a dependent agent, creating permanent establishment exposure for the foreign company. This is not a hypothetical risk: the Kazakh tax authority has assessed permanent establishment in pharmaceutical distribution arrangements in a number of recent audit cycles. The consequence is corporate income tax liability attributed to the deemed permanent establishment, plus penalties and interest.

EAEU-based entities — Russian, Belarusian, Armenian, Kyrgyz, or other EAEU-origin companies operating in Kazakhstan — benefit from the Eurasian Economic Union's harmonised pharmaceutical market framework, which simplifies product registration and, to a degree, customs duty treatment. However, EAEU membership does not create any special tax regime at the entity level. A Russian-owned Kazakh subsidiary is subject to the same Tax Code provisions as a German-owned one. The EAEU dimension is relevant for customs and regulatory licensing purposes but does not modify the corporate income tax or transfer-pricing analysis.

For entities considering Kazakhstan as a regional hub from which to supply other EAEU or CIS markets, the tax analysis becomes more complex. Kazakhstan does not operate a dedicated pharmaceutical special economic zone with corporate income tax holidays in the same way that some jurisdictions do, but certain investment contract regimes and special economic zones (SEZs) may offer preferential rates or reduced tax bases for qualifying investors who meet localisation, capital investment, and employment thresholds. Foreign pharmaceutical companies have used these instruments, though the qualification conditions are demanding and the benefits are subject to ongoing monitoring and potential clawback.

[CTA: For in-house counsel managing Kazakhstan operations alongside a broader EAEU portfolio, an initial consultation to map your exposure across entity type and supply chain structure is the practical starting point — info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

The regulatory landscape for foreign-owned pharmaceutical entities in Kazakhstan rewards proactive compliance posture and penalises reactive audit response. The following steps reflect the current enforcement environment.

First, any foreign-owned entity with cross-border intra-group transactions in Kazakhstan should treat transfer-pricing documentation as a live compliance obligation, not a filing that can be assembled after an audit notice is received. Kazakh tax legislation imposes documentation deadlines that mean contemporaneous documentation — prepared at the time of the transaction — is the practical standard for audit defence. Where documentation gaps exist for prior periods, a voluntary review and remediation exercise is advisable before the next scheduled audit cycle.

Second, entities operating through representative offices should conduct a periodic review of the activities actually performed by the office against the permitted scope under Kazakh law. The pharmaceutical sector is audit-active, and the risk of unintended permanent establishment characterisation is higher where the representative office has taken on functions — pricing approvals, contract negotiations, customer relationship management — that go beyond the permitted auxiliary scope.

Third, foreign companies using independent distributors should review their distribution agreements and the factual patterns of conduct against current permanent establishment case indicators. A distribution agreement that was structured correctly three years ago may now present a different risk profile if the factual conduct of the relationship has evolved.

Fourth, any entity considering a new Kazakhstan market entry — whether greenfield subsidiary, acquisition, or distribution arrangement — should seek integrated legal and tax advice at the structuring stage. The interaction between corporate income tax, VAT registration, pharmaceutical licensing requirements under the relevant regulatory body, and EAEU customs and registration rules is not linear; a structure optimised for one dimension may create unexpected exposure on another.

We are a Russian-qualified law firm. For Kazakhstan matters, we work with trusted regional counsel with specific Kazakhstan Tax Code and pharmaceutical regulatory expertise. We coordinate cross-border analysis where matters involve Russia and Kazakhstan simultaneously — a common configuration for EAEU pharmaceutical groups — and we can make introductions to local Kazakhstan counsel where standalone Kazakhstan advice is required.

[CTA: To discuss your Kazakhstan pharmaceutical entity's tax position, or to explore structuring options for a new market entry, make an enquiry at info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

Two areas of the Kazakhstan tax framework for the pharmaceutical sector remain in flux and warrant monitoring by foreign-owned entities.

The first is the interaction between pharmaceutical product registration and VAT treatment. The current linkage — under which VAT relief status is conditional on active product registration — creates a compliance synchronisation challenge: if a product's registration lapses during renewal proceedings, the VAT treatment of sales during the gap period is uncertain. Kazakh tax authority practice on this specific point has not been fully articulated in published guidance, and the risk is asymmetric for foreign companies that may have long renewal timelines managed by a local regulatory partner.

The second is the ongoing discussion within the EAEU framework about further harmonisation of pharmaceutical market access rules. Changes to EAEU-level regulation on mutual recognition of product registrations, or on the treatment of clinical trial data for registration purposes, have downstream implications for the regulatory preconditions that govern tax relief eligibility in member states including Kazakhstan. Foreign companies monitoring Kazakhstan developments in isolation, without tracking parallel EAEU-level developments, may find that their planning assumptions are displaced by changes originating at the supranational level.

Q: What specifically changed in Kazakhstan's tax treatment of foreign pharmaceutical companies? A: The core change is in enforcement posture and conditionality rather than headline rates. VAT relief on pharmaceutical products remains available but is now formally linked to product registration status and compliance standing. More significantly, transfer-pricing enforcement on cross-border intra-group pharmaceutical supply chains has intensified materially, with Kazakh tax inspectors applying OECD-aligned comparables analysis to API and finished-product pricing between related parties. Corporate income tax rates have not changed at the headline level. The practical effect is that entities that previously relied on informal compliance tolerance or light-touch documentation now face audit exposure that requires contemporaneous, structured transfer-pricing documentation.

Q: Which foreign pharmaceutical companies operating in Kazakhstan are most at risk from these changes? A: The highest exposure sits with foreign-owned Kazakh subsidiaries that import pharmaceutical products or APIs from related foreign entities at prices that were not set by reference to an arm's length analysis, and with foreign companies that use nominally independent Kazakh distributors but exercise significant operational control over those distributors' activities. Representative offices that have informally expanded their functions beyond permitted auxiliary activities also carry permanent establishment risk. EAEU-origin companies are not insulated from these exposures — EAEU membership does not alter the corporate income tax or transfer-pricing analysis at the entity level.

Q: What should a foreign pharmaceutical company do first if it has concerns about its Kazakhstan tax position? A: The most useful first step is a structured internal review of three things: the transfer-pricing documentation position on all current intra-group cross-border transactions involving the Kazakhstan entity; the factual scope of activities performed by any representative office or dependent personnel in Kazakhstan; and the distribution arrangements with local partners, reviewed against current permanent establishment risk indicators. That review should be done with counsel who has current Kazakhstan Tax Code expertise, and it should be completed before the next scheduled audit cycle rather than in response to an audit notice. Where the entity also has a Russian dimension — a common configuration in EAEU pharmaceutical groups — coordinated cross-border analysis is worthwhile given the interaction between Russian and Kazakh tax and customs frameworks.

• [Kazakhstan: market entry and company formation for foreign investors](/jurisdictions/kazakhstan/company-formation/)
• [Regulatory licensing in Kazakhstan: pharmaceutical sector requirements](/jurisdictions/kazakhstan/regulatory-licensing/)
• [Tax considerations for EAEU-based entities operating across member states](/insights/eaeu-tax-cross-border-considerations/)

Vetrov & Partners is a Russian boutique law firm established in 2009, recognised by Pravo-300 — Russia's principal legal directory — for eight consecutive years.

For foreign companies with interests spanning Russia and Kazakhstan — including EAEU pharmaceutical groups and inbound investors — we provide coordinated analysis and make introductions to trusted Kazakhstan counsel where standalone local advice is required. Our Kazakhstan coverage sits within a broader Central Asia and EAEU advisory capability built around cross-border market entry, tax structuring, regulatory licensing, and dispute resolution.

Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom

This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.

— Aigerim Serikbayeva Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs and Market Entry vetrovpartners.com/contributions/

Aigerim Serikbayeva advises on Kazakhstan and EAEU trade, customs, and market entry matters. She contributes regional analysis to Vetrov & Partners on cross-border matters involving Kazakhstan and Russia, with particular focus on regulated sectors including pharmaceuticals, and on the interaction between Kazakhstan national legislation and EAEU supranational rules.